leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...6465666768697071727374...235236»
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Vaxzevria (ChAdOx1-S recombinant) / Oxford Biomedica, Emergent Biosolutions, Jenner Institute, Vaccitech, AstraZeneca, University of Oxford, Spikevax (elasomeran) / Moderna
    Journal:  Drug-induced radiation recall reactions and non-anticancer drugs: A descriptive analysis from VigiBase®. (Pubmed Central) -  Jan 7, 2023   
    Our study first describes the occurrence of radiation recall reactions during non-anticancer treatment. It also highlights a potential safety signal with COVID-19 vaccines.
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion date, Trial primary completion date, Metastases:  NAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer (clinicaltrials.gov) -  Jan 6, 2023   
    P2,  N=44, Recruiting, 
    ClinicalTrials.gov Identifier: NCT01834235. Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Nov 2022 --> Nov 2023
  • ||||||||||  Bylantra (devimistat) / Cornerstone Pharma
    Trial completion date, Combination therapy, Metastases:  CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Jan 6, 2023   
    P1,  N=21, Active, not recruiting, 
    Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Nov 2022 --> Nov 2023 Trial completion date: Dec 2022 --> Apr 2023
  • ||||||||||  sirexatamab (DKN-01) / Leap Therap
    Phase classification, Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases:  DisTinGuish: A Study of DKN-01 in Combination With Tislelizumab  (clinicaltrials.gov) -  Jan 6, 2023   
    P2,  N=232, Recruiting, 
    Trial completion date: Dec 2022 --> Apr 2023 Phase classification: P2a --> P2 | N=72 --> 232 | Trial completion date: Jun 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Jun 2025
  • ||||||||||  tilatamig samrotecan (AZD9592) / AstraZeneca
    Enrollment open, Monotherapy:  EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov) -  Jan 6, 2023   
    P1,  N=108, Recruiting, 
    Phase classification: P2a --> P2 | N=72 --> 232 | Trial completion date: Jun 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Jun 2025 Not yet recruiting --> Recruiting
  • ||||||||||  Review, Journal:  Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management. (Pubmed Central) -  Jan 5, 2023   
    Recently published Phase II evidence and meta-analyses have supported the use of modern multi-agent regimens such as FOLFIRINOX...Though progress has been made, the optimal management of BR-PDAC is uncertain. Phase III trials utilizing modern chemotherapeutic regimens are needed to establish a standard of care.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Journal, Metastases:  FOLFOX-bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors. (Pubmed Central) -  Jan 5, 2023   
    Patients received a median of 17 cycles of treatment, including a median of seven cycles of bevacizumab and/or 5-fluorouracile maintenance...The FOLFOX-bevacizumab combination has promising efficacy in patients with progressive metastatic NETs and notably for G3 NETs, for which optimal treatment as yet remains ill-defined. Hence, it could be a relevant alternative to alkylating-based chemotherapy in this setting and should be further explored prospectively.
  • ||||||||||  Trial completion date, Trial primary completion date:  Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Jan 5, 2023   
    P2,  N=45, Recruiting, 
    Trial primary completion date: Mar 2026 --> Jun 2026 Trial completion date: Dec 2025 --> Jan 2030 | Trial primary completion date: Dec 2022 --> Jul 2027
  • ||||||||||  5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
    Enrollment open:  PIPAC and FOLFOX for Gastric Cancer Peritoneal Cancer (clinicaltrials.gov) -  Jan 5, 2023   
    P=N/A,  N=37, Recruiting, 
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Not yet recruiting --> Recruiting
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    COVID-19 VERSUS IMMUNE CHECKPOINT INHIBITOR MYOCARDITIS: A CLINICAL DILEMMA (Poster Hall_Hall F) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_1829;    
    It may be difficult to distinguish between ICI-myocarditis versus COVID-19 myocarditis based on cardiac biomarkers and non-invasive testing. This case highlights the dilemma as it has clinical implications for chemotherapy in this patient.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    5-FLUROURACIL INDUCED RAPIDLY REVERSIBLE SYSTOLIC DYSFUNCTION, REALLY REVERSIBLE? (Poster Hall_Hall F) -  Jan 4, 2023 - Abstract #ACCWCC2023ACC_WCC_978;    
    This case discussion is an attempt to look into the course of pathology and assess the prognosis, which though potentially bleak, may affect a patient's quality of life requiring frequent hospitalization. Although in this case, the patient had a quick recovery to his baseline LV systolic function, the global average strain remained abnormal, suggesting permanent changes in cardiac myocardium.
  • ||||||||||  leucovorin calcium / Generic mfg.
    Journal:  Untargeted metabolomics to evaluate antifungal mechanism: a study of Cophinforma mamane and Candida albicans interaction. (Pubmed Central) -  Jan 4, 2023   
    Several metabolites, including C20 sphinganine 1-phosphate, myo-inositol, farnesol, gamma-undecalactone, folinic acid, palmitoleic acid, and MG (12:/0:0/0:0) were not produced by CA during co-culture with CM, demonstrating the antifungal mechanism of CM. Our results highlight the crucial roles of metabolomics studies to provide essential information regarding the antifungal mechanism of C. mamane against C. albicans, especially when the lost/undetected metabolites are involved in fungal survival and pathogenicity.
  • ||||||||||  NP137 / NETRIS Pharma
    Anti-Netrin-1 Therapy Inhibits Metastasis and Improves Survival in Pancreatic Cancer (Ballroom A) -  Jan 3, 2023 - Abstract #SSO2023SSO_161;    
    These studies to show that Netrin-1 is driver of metastatic PC and that its upregulation can be exploited as a therapeutic vulnerability. The elucidation of the mechanism of upregulation through HSC secreted retinoic acid and the identification of NTN1 in EV
  • ||||||||||  5-fluorouracil / Generic mfg.
    Optimal Duration of Chemotherapy in the Era of Neoadjuvant Therapy for Pancreatic Adenocarcinoma - Is There a Magic Number? (Ballroom B) -  Jan 3, 2023 - Abstract #SSO2023SSO_156;    
    There was no difference in OS when comparing those patients who received FOLFIRINOX versus Gem/Abraxane (median 30.2 vs 29.1 mos; HR 1.26, p=0.21) or those that received only NAT versus NAT + AT (HR 0.83, p=0.52)... In this multi-institutional cohort of patients with resected PDAC who received NAT or NAT + AT, receipt of fewer than 6 month of total chemotherapy was associated with decreased overall survival, regardless of timing and chemotherapy regimen administered.
  • ||||||||||  Journal:  Diabetogenic liver metastasis from pancreatic cancer: a case report. (Pubmed Central) -  Dec 29, 2022   
    New-onset diabetes appeared with the progression of metachronous liver metastasis from pancreatic cancer, without recurrence at any other site. The patient's diabetic state was improved by resection of the liver tumor, and liver metastasis itself was proven to have caused the glucometabolic disorder by increasing insulin resistance.